Canada Markets open in 5 hrs 11 mins

Defence Therapeutics Inc. (DTC.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
6.420.00 (0.00%)
At close: 2:52PM EDT
Full screen
Previous Close6.42
Open0.00
Bid6.28 x N/A
Ask6.42 x N/A
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume13,155
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Defence Therapeutics Accum(TM) Variants in Vitro Study Increases the Potency of T-Deruxtecan ADC by 5-Fold on Breast Cancer

    Vancouver, British Columbia--(Newsfile Corp. - October 13, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines is pleased to announce strong in vitro results of its AccumTM variants on the recent Enhertu® (fam-trastuzumab-deruxtecan-nxki) ADC owned by AstraZeneca and Daiichi Sankyo. Defence has successfully selected and tested 5 AccumTM variants to the T-derux

  • Newsfile

    Defence Therapeutics Prepares for Phase I Trial to Test Its DC Cancer Vaccine, AccuVAC-D002, Against Melanoma

    Vancouver, British Columbia--(Newsfile Corp. - October 6, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines, is finalizing all required steps in preparation to a pre-IND meeting to initiate a phase I trial against melanoma using its DC cancer vaccine candidate AccuVAC-D002.Defence has successfully exploited the use of its AccumTM technology platform to deve

  • Newsfile

    Defence Therapeutics to Finalize Its Objectives to Initiate a Phase I Trial Against Breast Cancer

    Vancouver, British Columbia--(Newsfile Corp. - September 29, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology Company working on cancer therapeutics and infectious diseases vaccines, is pleased to announce that it will be conducting a series of final studies to complete all requirement needed to initiate a Phase I trial for one of its leading AccuTOX candidate against breast cancer. The AccumTM technology ...